Navigation Links
Boston Scientific Agrees to Sell Neurovascular Business to Stryker
Date:10/28/2010

n the operations of the Neurovascular business, the planned divestiture does not meet the criteria for presentation as a discontinued operation.  Accordingly, all historical financial results of the Neurovascular business will continue to be included in the Company's results from continuing operations for all periods presented.  In periods subsequent to closing, the Company's results will include only net sales to Stryker and an immaterial amount of gross profit related to those sales.

Boston Scientific established its Neurovascular business with the acquisition of Target Therapeutics in 1997.  Headquartered in Fremont, California, the Neurovascular business is a leading developer of less-invasive medical technologies used to treat brain aneurysms and other types of cerebrovascular disease.  The business employs approximately 1,150 people and reported 2009 revenues of $348 million.

"The sale of our Neurovascular business is part of our overall strategic plan that will refocus our portfolio to, amongst other criteria, leverage existing sales forces with least invasive, cost and comparatively effective medical devices that reduce or eliminate refractory drug regimens," said Ray Elliott, President and Chief Executive Officer of Boston Scientific.  "The proceeds from this sale will allow us to invest in future growth opportunities more aligned with that strategy while also reducing overall debt leverage.""We deeply appreciate the contributions of our Neurovascular employees and wish them continued success going forward in this new venture," added Elliott.  "We believe this transaction will prove to be a win-win for all parties."

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscien
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... on Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") ... of Directors ("Depomed Board") set a record date to ... The Depomed Board will review the ... is received today and contains the information required under ...
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... development portfolio building on lead product ... Phase 2 trial for onychomycosis, WELLESLEY HILLS, Mass., ... announced that it has,exercised the option it acquired in ... uses of pexiganan, a novel, small peptide,anti-infective for treatment ...
... BOULDER, Colo., Oct. 3 Tapestry,Pharmaceuticals, Inc. (Nasdaq: ... 2 open- label, multi-center study of TPI 287 in ... 2 trial exploring the,activity of TPI 287 in various ... year in advanced hormone refractory prostate cancer. "Currently ...
Cached Medicine Technology:MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 2MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 3MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 4MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 5MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 6Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 2Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 3Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 4Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 5
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... ... 04, 2015 , ... The Law Offices of Ben C. Martin , ... with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter lawyer for ... Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices and ...
(Date:8/4/2015)... Louis, MO (PRWEB) , ... August 04, 2015 ... ... attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report that ... Talcum powder lawyers provide regular news updates and cancer warning information ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing ... in support of an interaction simulation session entitled "NOACS: What the Evidence Shows ... by Medical Learning Institute Inc. and EDUmotion US LLC. , This special activity ...
(Date:8/4/2015)... ... 2015 , ... Lightning Labels is pleased to announce the ... usher in a new standard of sticker and label-making for the company. , ... twin objectives of quality and quantity without compromising the signature lightning-fast speed we ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3
... Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... a proprietary breast drug from,Harbin Medical University ...
... Contribute to Blood Vessels, Healthy ... Ability to Relax, ... component of soy may enhance the function of arteries,in stroke patients, and ... and Prevention, heart disease is the,nation,s number one killer while stroke is ...
... Oct. 28 The Los Angeles Shambhala Center,presents a public ... the weekend, Oct 30 and November 1st and 2nd., ... Japan will,appear for the first time in Los Angeles at ... at Figueroa and Colorado Blvd.,in Eagle Rock., On Thursday, ...
... WellSpring Pharmaceutical,Corporation, a growing North American-based pharmaceutical manufacturer,today ... Operating Officer.,Formerly, Ms. Shusko held the position of ... 2000. In her new role as COO, Ms. ... of oversight,to operations with an initial focus on ...
... /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) ... initial closing of the financing announced on October,14, ... gross proceeds of $4.66,million. The closing involved a ... a price of $0.15 for each unit. Each ...
... for internet-based public reporting to help consumers ... WASHINGTON Oct. 28 To support consumer,engagement ... Quality Forum,(NQF) endorsed guidelines for consumer-focused, internet-based ... to present,information about hospital quality in an ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 3Health News:Study Shows How Soy Compound Lowers Blood Pressure and Stroke Risk 2Health News:Renowned Kyudo (Zen archery) Master Kanjuro Shibata Sensei to Present in L.A. 2Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 3Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 5
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Active Cath is a latex, self-adhering, one piece catheter designed for extended wear. It combines a shortened latex sheath with a wide adhesive seal....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Medicine Products: